Somewhat Negative News Coverage Somewhat Unlikely to Impact ASLAN PHARMACEUTICALS ADR REP 5 (ASLN) Stock Price

News articles about ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) have been trending somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ASLAN PHARMACEUTICALS ADR REP 5 earned a news impact score of 0.00 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 43.9036605669493 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several research firms recently weighed in on ASLN. Leerink Swann began coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “market perform” rating and a $7.00 price target for the company. BTIG Research initiated coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “buy” rating and a $16.00 price target for the company. Piper Jaffray Companies initiated coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set an “overweight” rating for the company. Finally, HC Wainwright initiated coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “buy” rating and a $12.00 target price for the company.

ASLAN PHARMACEUTICALS ADR REP 5 traded down $0.15, reaching $9.05, on Thursday, Marketbeat.com reports. 400 shares of the company’s stock were exchanged, compared to its average volume of 147,385. ASLAN PHARMACEUTICALS ADR REP 5 has a 52 week low of $5.08 and a 52 week high of $10.44.

About ASLAN PHARMACEUTICALS ADR REP 5

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm’s portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways.

Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply